The focus of the 2012 Annual Meeting of the CMSC is "to provide MS healthcare professionals with the most up-to-date information impacting patient care in the areas of research, disease modification, epidemiology, quality of life, neuroimaging, gender specific issues..." and more. Highlights from the conference will include case-based learning, technological advances in clinical care and research, clinical care, and basic research and clinical trials.
2012 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC)

2012 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) | CMSC 2012

Conference Coverages

CMSC 2012: Oral Teriflunomide Not Superior to Interferon in Risk of Treatment Failure
The oral disease-modifying drug under development for the treatment of relapsing-remitting multiple sclerosis, teriflunomide, was not superior to interferon beta-1a in risk of treatment failure.
CMSC 2012: Immune Parameters Normalize Within 4 Months of Natalizumab Cessation in the Treatment of RRMS
In the course of a 24-week cessation of treatment with the humanized monoclonal antibody, natalizumab, in patients with RRMS, pharmacokinetic, pharmacodynamic, and serum immune parameters normalized by 4 months.
CMSC 2012: Ischemic Heart Disease and Myocardial Infarction Occur Less Frequently in Hospital Discharges with Multiple Sclerosis
People discharged from the hospital with MS are 30% less likely to have had a myocardial infarction and 58% less likely to have ischemic heart disease.
CMSC 2012: Dimethyl Fumarate Improves Annualized Relapse Rate and Risk of Relapse in Patients With RRMS
Treatment with the investigational oral treatment for relapsing-remitting multiple sclerosis, dimethyl fumarate (aka BG-12), yielded significant reductions in the annualized relapse rate and risk of relapse.
CMSC 2012: Natalizumab Interruption Results in a High Rate of MRI and Clinical MS Disease Activity Recurrence
After a 24-week cessation of natalizumab treatment, a high rate of MRI and clinical disease activity recurs in patients with multiple sclerosis.
CMSC 2012: Alemtuzumab Efficacy in RRMS Patients Who Relapsed on Prior Therapy
The monoclonal antibody, alemtuzumab, significantly reducesthe number of relapses and the accumulation of disability in patients with relapsing-remitting multiple sclerosis who had relapsed on prior therapy.
CMSC 2012: Fingolimod Slows Brain Volume Loss and May Be Neuroprotective
The once-daily oral MS drug, fingolimod, slows brain volume loss in patients with MS, regardless of inflammatory activity.

Most Popular

$vacMongoViewPlus$ $vAR$